Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (December 2025)
59 slides from Anteris Technologies Global's shareholder meeting presentation, Dec 4, 2025
Slide 1: Annual Meeting - Vice Chairman and Chief Executive Officer Presentation
Annual Meeting - Vice Chairman and Chief Executive Officer Presentation MINNEAPOLIS, United States and BRISBANE, Australia 4 December 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and com
Slide 2: Annual Meeting December 2025
For personal use only Annual Meeting December 2025 NASDAQ: AVR | ASX: AVR
Slide 3: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and For personal use only clinical trials and studies. Any statements about our expectati
Slide 4: Disclaimer: Non-GAAP Financial Measures
Disclaimer Non-GAAP Financial Measures For personal use only This presentation includes a discussion of our operating spend, which is an unaudited financial measure that is not based on any standardized methodology prescribed by U.S. generally accepted accounting principles (GAAP) and may be calcula
Slide 5: For personal use only
For personal use only
Slide 6: Leading the Field
For personal use only Leading the Field
Slide 7: For personal use only
For personal use only
Slide 8: FY2024 Key Numbers
FY2024 Key Numbers For personal use only CASH 136.1 * $70.5M * EMPLOYEES & CONTRACTORS Compared to $21.1M FTE supporting Anteris’ at Dec 31, 2023 business strategy 41.2% CAPITAL RAISED R&D COSTS IN 2024 $51.5M $125.9M Compared to $30.9M in 2023 Including IPO 66.6% All amounts are in USD Percenta
Slide 9: Key 2025 Highlights
Key 2025 Highlights For personal use only 159.9 * CASH $9.1M * EMPLOYEES & CONTRACTORS Compared to $70.5M FTE supporting Anteris’ at Dec 31, 2024 business strategy 41.2% since Dec 2024 R&D COSTS* Q4 2025 Q4 2025 YTD 9 MONTHS PRIVATE PLACEMENT REGULATORY $25.2M $49.6M APPROVALS COMPARED TO $38.1M r
Slide 10: Focused R&D Expenditures Driving the Path to Approval
Focused R&D Expenditures Driving the Path to Approval Research and Development Costs ResearchR&Dand Development For personal use only Driving Innovation: is 76.4% of our operating spend1 • PARADIGM trial preparatory costs • Expansion of clinical field team 76.4% • Upscaling manufacturing capabilitie
Slide 11: Reconciliation of R&D expenditures to Operating spend
Reconciliation of R&D expenditures to Operating spend 12 months 12 months 9 months For personal use only Dec 31, 2023 Dec 31, 2024 Sept 30, 2025 $M 1 $M 1 $M 2 Research & Development expense (R&D) Total R&D disclosed in Forms 10-K and 10-Q 30.9 51.5 49.6 Stock-based compensation expense related to R
Slide 12: Positive FX Impact Linked to Decline in AUD
Positive FX Impact Linked to Decline in AUD 0.80 For personal use only 0.75 5-year average: 1 AUD = 0.68 USD YTD 2025 average: 1 AUD = 0.64 USD 0.70 0.65 0.60 0.55 Nov-2020 May-2021 Nov-2021 May-2022 Nov-2022 May-2023 Nov-2023 May-2024 Nov-2024 May-2025 Nov-2025 Source: Reserve Bank of Australia, St
Slide 13: Positive FX Impact Linked to Decline in AUD
Positive FX Impact Linked to Decline in AUD AUD For personal use only 12.0 10.4M 10.0 USD USD 7.4M USD AUD 10.4M of expenses 8.0 7.1M • 6.7M incurred in YTD Sept 2025 converted into USD 6.7M MILLIONS 6.0 • The same AUD 10.4M using the prior 10-year average FX 4.0 rate converts into USD 7.4M 2.0 0.0
Slide 14: Access to Capital Has Increased With Our Data!
For personal use only Access to Capital Has Increased With Our Data !
Slide 15: Continued Institutional Support
Continued Institutional Support For personal use only • Top shareholders continue to demonstrate strong support • Concentrated ownership among high-quality, physician-led institutional investors • Since IPO, mix of top 20 shareholders shifted to the US • Greater than 10-fold increase in liquidity (v
Slide 16: Ongoing Large Shareholder and New Institutional Support
Ongoing Large Shareholder and New Institutional Support For personal use only Capital placements - funds raised • On-going support reflects confidence in the Company’s strategy and clinical progress 24% 32% 20% • Strong engagement with leading investors • 95%+ of funds raised in recent capital 76% 6
Slide 17: Building a Strong, Global Workforce
Building a Strong, Global Workforce Workforce by Function Workforce by Geography For personal use only Exec & Board HR, IT, Finance, Europe incl. support, 3% Investor 8% Relations, 14% Australia 26% R&D, Manufacturing, USA Regulatory & 52% 66% Medical, Marketing, PMO, 32% Employees & Contractors 159
Slide 18: Building a Strong, Diverse & Inclusive Workforce
Building a Strong, Diverse & Inclusive Workforce FTE BY FUNCTION GENDER DIVERSITY For personal use only SG&A 16% 25.7 FTE Male 41% Female 134.2 FTE 59% R&D incl. manufacturing 84% September 30, 2025 Leadership and Management: 51% Male / 49% Female Employees & Contractors: 159.9 FTE 17.5% (23.8 FTE
Slide 19: Building a Strong, Diverse & Inclusive Workforce
Building a Strong, Diverse & Inclusive Workforce For personal use only Norway Sweden England Albania Canada Ireland Germany Algeria Inclusive and USA France Switzerland Ukraine Collaborative Celebrating our Mexico Netherlands Spain Italy Iran China Driving Innovation Ethnic Diversity Puerto Rico Ind
Slide 20: Setting Up a Structure For the Future
NASDAQ Setting Up a Structure For the Future For personal use only
Slide 21: 2024 Re-Domiciliation and US IPO
2024 Re-Domiciliation and US IPO • Re-domiciled from Australia to US end of 2024 (Anteris Technologies Global Corp new parent) For personal use only • Strong support from shareholders and option holders • Listed common stock on the Nasdaq and CDIs on the ASX • IPO raising USD 88.8M , AUD 135M (gross
Slide 22: Liquidity Has Increased Over 1000% Since Nasdaq Trading
Liquidity Has Increased Over 1000% Since Nasdaq For personal use only Trading Volume
Slide 23: AVR Stock Price Movements
AVR Stock Price Movements $10.00 MARCH 2025 Director appointed For personal use only $9.00 NOVEMBER 2025 FDA approval – PARADIGM trial JUNE 2025 $8.00 New Directors appointed DECEMBER 2024 SEPTEMBER 2025 $7.00 Nasdaq IPO ASX Listing Rule 7.1 Waiver APRIL 2025 US ‘Liberation Day’ shareholder approval
Slide 24: How Do We Compare to Newly Listed Small Cap MedTechs?
How Do We Compare to Newly Listed Small Cap MedTechs ? First MedTechs listed in approx 3 years For personal use only
Slide 25: Stock Volatility Follows the Market
Stock Volatility Follows the Market For personal use only
Slide 26: For personal use only
For personal use only 27
Slide 27: A Chat with Dr Chris
For personal use only Dr Chris A Chat with
Slide 28: Being Normal As a Company In This Space Was Never The Target
Being Normal As a Company In This For personal use only Space Was Never The Target
Slide 29: But Bringing Patients Back To a Normal State Was
But Bringing For personal use only Patients Back To a Normal State Was
Slide 30: Unpacking the Clinical Data
For personal use only Unpacking the Clinical Data
Slide 31: DurAVR THV: A New Class of TAVR
DurAVR® THV: A New Class of TAVR Single piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve For personal use only
Slide 32: DurAVR Only THV to Demonstrate Restoration of Physiologic Laminar Flow
DurAVR® Only THV to Demonstrate Restoration of Physiologic Laminar Flow Healthy Aortic Valve Post DurAVR® THV Post DurAVR® THV For personal use only FD = 10% FRR = 1% FD = 14% FRR = 4% FD = Flow Displacement, FRR = Flow Reversal Ratio Courtesy of Dr. Pankaj Garg, Norwich University Hospital (UK) Dat
Slide 33: For personal use only
For personal use only
Slide 34: For personal use only
For personal use only
Slide 35: DurAVR THV Small Aortic Annuli Pooled Cohort
DurAVR® THV Small Aortic Annuli Pooled Cohort Symptomatic Severe Native Aortic Stenosis For personal use only EMBARK DurAVR® THV US EFS EU EFS Small Valve Study DurAVR S Valve DurAVR S Valve DurAVR S Valve N=74 N=15 N=11 30-Day Follow- 30-Day Follow- 30-Day Follow- up up up N=74 N=15 N=11 Area: 346-
Slide 36: Procedural Success Across Variety of Anatomies
Procedural Success Across Variety of Anatomies Challenging anatomies treated Technical success: 93% Device success: 91% For personal use only Severe annular calcium Extreme leaflet calcium Type 1 bicuspid Extreme LVOT calcium Predictable BE placement pcrlondonvalves.com
Slide 37: Baseline Echo and CT Characteristics
Baseline Echo and CT Characteristics DurAVR® THV For personal use only Baseline Echo and CT Characteristics (N=100) Aortic annulus area, mm2 404 ± 37 Aortic annulus mean diameter, mm 22.7 ± 1.0 Aortic valve area, cm2 0.8 ± 0.2 Mean transvalvular gradient, mmHg 48.1 ± 17.0 Left ventricular ejection f
Slide 38: Favorable Hemodynamics Through Days
Favorable Hemodynamics Through 30 Days Single-digit mean gradient and No moderate or severe 97% freedom from ≥ moderate large effective orifice area paravalvular leak prosthesis-patient mismatch For personal use only DVI = 0.60 pcrlondonvalves.com
Slide 39: Hemodynamics and PPM in Small Annuli at Days
Hemodynamics and PPM in Small Annuli at 30 Days Low rate of moderate or Single-digit mean gradient Large EOA severe prosthesis-patient For personal use only mismatch 1,2 1,2 1,2 Error bars represent standard deviation 1. Hermann HC et al. NEMJ. 2024;390:1957-71. 2. Presented by Hermann HC SCAI 2024:
Slide 40: For personal use only
For personal use only
Slide 41: PARADIGM Trial Design
PARADIGM Trial Design Severe Native Aortic Stenosis Failed Surgical Bioprosthesis Cohort For personal use only All Comers Randomized Cohort Low Risk Randomized Cohort Valve-in-Valve Cohort Assessment for Eligibility Assessment for Eligibility Assessment for Eligibility All Risk Candidate Low Risk Ca
Slide 42: Experience Matters: Clinical, Manufacturing, Launch
For personal use only Experience Matters Clinical, Manufacturing, Launch
Slide 43: A Very Experienced Clinical Trial Team
A Very Experienced Clinical Trial Team Total culminative amount of clinical studies that current Anteris employees have been instrumental in successfully delivering: For personal use only Spanning cardiovascular devices, regulatory affairs, and medical leadership across global markets 68 US Clinical
Slide 44: What Else Do We Need?
For personal use only What Else Do We Need?
Slide 45: We Have a World Class Experienced Team Across All Areas
We Have a World Class Experienced Team Across All Areas For personal use only • VP of RA has filed for multiple approvals from one of the big MedTechs • VP Manufacturing was Head of Global TAVR manufacturing at one of the big MedTechs • VP QC was head of QC at of the Big MedTechs • Clinical Field te
Slide 46: For personal use only
For personal use only
Slide 47: Pivot From Rx Co to MedTech - A High Risk But Necessary Strategy
Pivot From Rx Co to MedTech - A High Risk But Necessary Strategy 100 DurAVR® Patients For personal use only Doctors & Patients Needs: Balloon IDE Submission Formation of Anteris’ Expandable delivery THV Medical Advisory determined with Key animal study for Board EU Reg Clearance hemodynamic EFS Subm
Slide 48: TAVR Market Opportunity Expected to Reach USD 9.9BN in 2028
TAVR Market Opportunity Expected to Reach USD 9.9BN in 2028 Underpenetrated patient population with only 15-20%1 of severe aortic stenosis cases treated today For personal use only TAVR Aortic Stenosis & Valve-in-Valve Market2 Potential for further significant growth 14.0 Currently 3 industry trials
Slide 49: Value Proposition
Value Proposition For personal use only Anteris has a compelling clinical Current Market Leader proposition New Entrant Edwards Lifesciences Anteris Technologies Shares outstanding Shares outstanding 580.7 million 41.2 million as of Sept 30, 2025 as of Nov 12, 2025 USD 86.67 USD 4.10 Share price(a)
Slide 50: Anteris is Leading the Field
For personal use only Anteris is Leading the Field
Slide 51: For personal use only
For personal use only
Slide 52: For personal use only
For personal use only
Slide 53: Board of Directors
Board of Directors For personal use only John Seaberg Wayne Paterson Stephen Denaro CHAIRMAN VICE CHAIRMAN & CEO DIRECTOR Dave Roberts Greg Moss David St Denis NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR PRESIDENT & DIRECTOR
Slide 54: Highly Experienced Leadership – Clinical, Operational, Commercial
Highly Experienced Leadership – Clinical, Operational, Commercial For personal use only Wayne Paterson David St Denis VICE CHAIRMAN & CEO PRESIDENT & DIRECTOR Matthew McDonnell Dr. Chris Meduri CHIEF FINANCIAL OFFICER CHIEF MEDICAL OFFICER
Slide 55: Our Physician Advisors
For personal use only Our Physician Advisors
Slide 56: Our Visionary Investors
For personal use only Our Visionary Investors
Slide 57: And of Course Our Patients
[] For personal use only And of Course Our Patients
Slide 58: Anteris is Leading the Field
For personal use only Anteris is Leading the Field
Slide 59: For personal use only
For personal use only
Anteris Technologies Global — Shareholder Meeting (December 2025) on 6ix